Adeno-associated Viral (AAV) Vector-mediated Therapeutics for Diabetic Cardiomyopathy - Current and Future Perspectives

Overview

Journal Clin Sci (Lond)

Specialties Biochemistry
General Medicine
Science

Date 2021 Jun 2

PMID 34076247

Citations 7

Authors

Darnel Prakoso

Mitchel Tate

Miles J De Blasio

Rebecca H Ritchie

Affiliations

Soon will be listed here.

Abstract

Diabetes increases the prevalence of heart failure by 6-8-fold, independent of other comorbidities such as hypertension and coronary artery disease, a phenomenon termed diabetic cardiomyopathy. Several key signalling pathways have been identified that drive the pathological changes associated with diabetes-induced heart failure. This has led to the development of multiple pharmacological agents that are currently available for clinical use. While fairly effective at delaying disease progression, these treatments do not reverse the cardiac damage associated with diabetes. One potential alternative avenue for targeting diabetes-induced heart failure is the use of adeno-associated viral vector (AAV) gene therapy, which has shown great versatility in a multitude of disease settings. AAV gene therapy has the potential to target specific cells or tissues, has a low host immune response and has the possibility to represent a lifelong cure, not possible with current conventional pharmacotherapies. In this review, we will assess the therapeutic potential of AAV gene therapy as a treatment for diabetic cardiomyopathy.

Citing Articles

Advanced delivery systems for gene editing: A comprehensive review from the GenE-HumDi COST Action Working Group.

Cavazza A, Molina-Estevez F, Plaza Reyes A, Ronco V, Naseem A, Malensek S Mol Ther Nucleic Acids. 2025; 36(1):102457.

PMID: 39991472 PMC: 11847086. DOI: 10.1016/j.omtn.2025.102457.

The promising potential of gene therapy for diabetes mellitus.

Bornstein S, Wright J, Steenblock C Nat Rev Endocrinol. 2024; 20(11):627-628.

PMID: 39209975 DOI: 10.1038/s41574-024-01030-7.

Update on clinical and experimental management of diabetic cardiomyopathy: addressing current and future therapy.

Galis P, Bartosova L, Farkasova V, Bartekova M, Ferenczyova K, Rajtik T Front Endocrinol (Lausanne). 2024; 15:1451100.

PMID: 39140033 PMC: 11319149. DOI: 10.3389/fendo.2024.1451100.

Machine-learning-guided Directed Evolution for AAV Capsid Engineering.

Fu X, Suo H, Zhang J, Chen D Curr Pharm Des. 2024; 30(11):811-824.

PMID: 38445704 DOI: 10.2174/0113816128286593240226060318.

Immune cells drive new immunomodulatory therapies for myocardial infarction: From basic to clinical translation.

Nian W, Huang Z, Fu C Front Immunol. 2023; 14:1097295.

PMID: 36761726 PMC: 9903069. DOI: 10.3389/fimmu.2023.1097295.

References

Wang D, Tai P, Gao G . Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019; 18(5):358-378. PMC: 6927556. DOI: 10.1038/s41573-019-0012-9. View

Loke Y, Kwok C, Singh S . Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011; 342:d1309. PMC: 3230110. DOI: 10.1136/bmj.d1309. View

Yoshida Y, Yamanaka S . An emerging strategy of gene therapy for cardiac disease. Circ Res. 2012; 111(9):1108-10. DOI: 10.1161/CIRCRESAHA.112.278820. View

Woitek F, Zentilin L, Hoffman N, Powers J, Ottiger I, Parikh S . Intracoronary Cytoprotective Gene Therapy: A Study of VEGF-B167 in a Pre-Clinical Animal Model of Dilated Cardiomyopathy. J Am Coll Cardiol. 2015; 66(2):139-53. PMC: 4499859. DOI: 10.1016/j.jacc.2015.04.071. View

Bowes C, Lien L, Butler J . Clinical aspects of heart failure in individuals with diabetes. Diabetologia. 2019; 62(9):1529-1538. DOI: 10.1007/s00125-019-4958-2. View

. Gene therapy's next installment. Nat Biotechnol. 2019; 37(7):697. DOI: 10.1038/s41587-019-0194-z. View

Kannel W, Hjortland M, CASTELLI W . Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974; 34(1):29-34. DOI: 10.1016/0002-9149(74)90089-7. View

Meloni M, Caporali A, Graiani G, Lagrasta C, Katare R, Van Linthout S . Nerve growth factor promotes cardiac repair following myocardial infarction. Circ Res. 2010; 106(7):1275-84. PMC: 2881000. DOI: 10.1161/CIRCRESAHA.109.210088. View

Katz M, Fargnoli A, Swain J, Tomasulo C, Ciccarelli M, Huang Z . AAV6-βARKct gene delivery mediated by molecular cardiac surgery with recirculating delivery (MCARD) in sheep results in robust gene expression and increased adrenergic reserve. J Thorac Cardiovasc Surg. 2011; 143(3):720-726.e3. PMC: 3666102. DOI: 10.1016/j.jtcvs.2011.08.048. View

10.

Ti Y, Xie G, Wang Z, Bi X, Ding W, Wang J . TRB3 gene silencing alleviates diabetic cardiomyopathy in a type 2 diabetic rat model. Diabetes. 2011; 60(11):2963-74. PMC: 3198078. DOI: 10.2337/db11-0549. View

11.

Hinkel R, Lange P, Petersen B, Gottlieb E, Man Ng J, Finger S . Heme Oxygenase-1 Gene Therapy Provides Cardioprotection Via Control of Post-Ischemic Inflammation: An Experimental Study in a Pre-Clinical Pig Model. J Am Coll Cardiol. 2015; 66(2):154-65. DOI: 10.1016/j.jacc.2015.04.064. View

12.

Penpargkul S, Fein F, SONNENBLICK E, Scheuer J . Depressed cardiac sarcoplasmic reticular function from diabetic rats. J Mol Cell Cardiol. 1981; 13(3):303-9. DOI: 10.1016/0022-2828(81)90318-7. View

13.

Meloni M, Descamps B, Caporali A, Zentilin L, Floris I, Giacca M . Nerve growth factor gene therapy using adeno-associated viral vectors prevents cardiomyopathy in type 1 diabetic mice. Diabetes. 2011; 61(1):229-40. PMC: 3237667. DOI: 10.2337/db11-0763. View

14.

Hayward C, Banner N, Morley-Smith A, Lyon A, Harding S . The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective. Hum Gene Ther. 2015; 26(5):293-304. DOI: 10.1089/hum.2015.018. View

15.

Liu X, Simpson J, Brunt K, Ward C, Hall S, Kinobe R . Preemptive heme oxygenase-1 gene delivery reveals reduced mortality and preservation of left ventricular function 1 yr after acute myocardial infarction. Am J Physiol Heart Circ Physiol. 2007; 293(1):H48-59. DOI: 10.1152/ajpheart.00741.2006. View

16.

Sanbe A, Gulick J, Hanks M, Liang Q, Osinska H, Robbins J . Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res. 2003; 92(6):609-16. DOI: 10.1161/01.RES.0000065442.64694.9F. View

17.

Nathan D, Cleary P, Backlund J, Genuth S, Lachin J, Orchard T . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25):2643-53. PMC: 2637991. DOI: 10.1056/NEJMoa052187. View

18.

Dai B, Li H, Fan J, Zhao Y, Yin Z, Nie X . MiR-21 protected against diabetic cardiomyopathy induced diastolic dysfunction by targeting gelsolin. Cardiovasc Diabetol. 2018; 17(1):123. PMC: 6122727. DOI: 10.1186/s12933-018-0767-z. View

19.

Prakoso D, De Blasio M, Qin C, Rosli S, Kiriazis H, Qian H . Phosphoinositide 3-kinase (p110α) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction. Clin Sci (Lond). 2017; 131(12):1345-1360. DOI: 10.1042/CS20170063. View

20.

Seferovic P, Coats A, Ponikowski P, Filippatos G, Huelsmann M, Jhund P . European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. Eur J Heart Fail. 2019; 22(2):196-213. DOI: 10.1002/ejhf.1673. View